Ark agrees manufacturing deal with Glasgow University
To support development of gene-therapy programme for treating vein graft failure
Ark Therapeutics Group has signed a manufacturing agreement with the University of Glasgow’s Institute of Cardiovascular and Medical Sciences under which Ark will provide manufacturing and related services to support the development of the Institute’s gene-therapy programme for the treatment of vein graft failure associated with coronary artery bypass surgery.
London, UK-based Ark will manufacture for the University of Glasgow cGMP grade adenoviral vector expressing TIMP3 gene to be administered ex vivo to vein grafts during coronary artery bypass surgery in the University’s first-in-man Phase I/II trial to reduce vein graft failure.
Financial details of the agreement were not disclosed.
Professor Anna Dominiczak, head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, said: ‘It is crucial that we work with an experienced company for provision of clinical grade reagents for our clinical trial, which if successful will make a substantial difference to the long-term success of heart bypass procedures.’
